Cargando…
A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing
Cancer becomes one of the main causes of human deaths in the world due to the high incidence and mortality rate and produces serious economic burdens. With more and more attention is paid on cancer, its therapies are getting more of a concern. Previous research has shown that the occurrence, progres...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353945/ https://www.ncbi.nlm.nih.gov/pubmed/35935840 http://dx.doi.org/10.3389/fphar.2022.939090 |
_version_ | 1784762963914129408 |
---|---|
author | Chen, Xin-Zhu Guo, Rong Zhao, Cong Xu, Jing Song, Hang Yu, Hua Pilarsky, Christian Nainu, Firzan Li, Jing-Quan Zhou, Xin-Ke Zhang, Jian-Ye |
author_facet | Chen, Xin-Zhu Guo, Rong Zhao, Cong Xu, Jing Song, Hang Yu, Hua Pilarsky, Christian Nainu, Firzan Li, Jing-Quan Zhou, Xin-Ke Zhang, Jian-Ye |
author_sort | Chen, Xin-Zhu |
collection | PubMed |
description | Cancer becomes one of the main causes of human deaths in the world due to the high incidence and mortality rate and produces serious economic burdens. With more and more attention is paid on cancer, its therapies are getting more of a concern. Previous research has shown that the occurrence, progression, and treatment prognosis of malignant tumors are closely related to genetic and gene mutation. CRISPR/Cas9 has emerged as a powerful method for making changes to the genome, which has extensively been applied in various cell lines. Establishing the cell and animal models by CRISPR/Cas9 laid the foundation for the clinical trials which possibly treated the tumor. CRISPR-Cas9-mediated genome editing technology brings a great promise for inhibiting migration, invasion, and even treatment of tumor. However, the potential off-target effect limits its clinical application, and the effective ethical review is necessary. The article reviews the molecular mechanisms of CRISPR/Cas9 and discusses the research and the limitation related to cancer clinical trials. |
format | Online Article Text |
id | pubmed-9353945 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93539452022-08-06 A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing Chen, Xin-Zhu Guo, Rong Zhao, Cong Xu, Jing Song, Hang Yu, Hua Pilarsky, Christian Nainu, Firzan Li, Jing-Quan Zhou, Xin-Ke Zhang, Jian-Ye Front Pharmacol Pharmacology Cancer becomes one of the main causes of human deaths in the world due to the high incidence and mortality rate and produces serious economic burdens. With more and more attention is paid on cancer, its therapies are getting more of a concern. Previous research has shown that the occurrence, progression, and treatment prognosis of malignant tumors are closely related to genetic and gene mutation. CRISPR/Cas9 has emerged as a powerful method for making changes to the genome, which has extensively been applied in various cell lines. Establishing the cell and animal models by CRISPR/Cas9 laid the foundation for the clinical trials which possibly treated the tumor. CRISPR-Cas9-mediated genome editing technology brings a great promise for inhibiting migration, invasion, and even treatment of tumor. However, the potential off-target effect limits its clinical application, and the effective ethical review is necessary. The article reviews the molecular mechanisms of CRISPR/Cas9 and discusses the research and the limitation related to cancer clinical trials. Frontiers Media S.A. 2022-07-22 /pmc/articles/PMC9353945/ /pubmed/35935840 http://dx.doi.org/10.3389/fphar.2022.939090 Text en Copyright © 2022 Chen, Guo, Zhao, Xu, Song, Yu, Pilarsky, Nainu, Li, Zhou and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Chen, Xin-Zhu Guo, Rong Zhao, Cong Xu, Jing Song, Hang Yu, Hua Pilarsky, Christian Nainu, Firzan Li, Jing-Quan Zhou, Xin-Ke Zhang, Jian-Ye A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing |
title | A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing |
title_full | A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing |
title_fullStr | A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing |
title_full_unstemmed | A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing |
title_short | A Novel Anti-Cancer Therapy: CRISPR/Cas9 Gene Editing |
title_sort | novel anti-cancer therapy: crispr/cas9 gene editing |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9353945/ https://www.ncbi.nlm.nih.gov/pubmed/35935840 http://dx.doi.org/10.3389/fphar.2022.939090 |
work_keys_str_mv | AT chenxinzhu anovelanticancertherapycrisprcas9geneediting AT guorong anovelanticancertherapycrisprcas9geneediting AT zhaocong anovelanticancertherapycrisprcas9geneediting AT xujing anovelanticancertherapycrisprcas9geneediting AT songhang anovelanticancertherapycrisprcas9geneediting AT yuhua anovelanticancertherapycrisprcas9geneediting AT pilarskychristian anovelanticancertherapycrisprcas9geneediting AT nainufirzan anovelanticancertherapycrisprcas9geneediting AT lijingquan anovelanticancertherapycrisprcas9geneediting AT zhouxinke anovelanticancertherapycrisprcas9geneediting AT zhangjianye anovelanticancertherapycrisprcas9geneediting AT chenxinzhu novelanticancertherapycrisprcas9geneediting AT guorong novelanticancertherapycrisprcas9geneediting AT zhaocong novelanticancertherapycrisprcas9geneediting AT xujing novelanticancertherapycrisprcas9geneediting AT songhang novelanticancertherapycrisprcas9geneediting AT yuhua novelanticancertherapycrisprcas9geneediting AT pilarskychristian novelanticancertherapycrisprcas9geneediting AT nainufirzan novelanticancertherapycrisprcas9geneediting AT lijingquan novelanticancertherapycrisprcas9geneediting AT zhouxinke novelanticancertherapycrisprcas9geneediting AT zhangjianye novelanticancertherapycrisprcas9geneediting |